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Abstract 
A wide spectrum of diseases or conditions (genetically based or acquired), in the presence of triggering elements, 
can lead to arrhythmic events, having sudden death as a common result. The substrate of fatal arrhythmia de-
pends on age: over 35 years old it is mainly represented by the instability of coronary heart disease. Up to 35 
years of age, the substrate consists mainly of electrical or structural alterations of the heart of a genetic nature the 
main of which are i) idiopathic hypertrophic cardiomyopathy ii) arrhythmogenic cardiomyopathy of the right 
ventricle iii) congenital syndrome of long QT iv) congenital syndrome of short QT; 
v) Brugada syndrome. Each of these proarrhythmic genetic conditions has the prerogative of being able to be 
highlighted by an electrocardiogram: a simple and economical gesture that can lead directly to an important diag-
nosis, or at least make it suspected, addressing the subsequent evaluations. Formulating a diagnosis of this kind 
can minimize the risk of sudden death, through careful use of lifestyle advice, drugs, devices, procedures. It has 
been scientifically proved that identifying genetic conditions at risk of malignant arrhythmias in the athlete leads 
to a dramatic reduction in the risk of sudden death: on this basis, an electrocardiographic screening has become 
peremptory in many countries in order to be able to perform competitive sports (in Italy, for some years, also to 
be able to carry out non-competitive sports). Electrocardiographic screening should be considered for the entire 
youth population, regardless of participation in an organized sports activity program, as this can potentially mean 
saving young lives from sudden death. 
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Introduction 
 
Sudden cardiac death (SCD) in young adults 
(<35 years) is an emotionally staggering event, 
not only for the victim’s family but also for the 
community. Although the precise incidence of 
this catastrophic event is not exactly known 
around the world, in the USA it ranges between 
0.8 and 8 deaths per 100,000/year (Vetter 2014, 
688–97). As everywhere, even in Salento the 
SCD in young people is not a negligible event: 
the case of Lorenzo T., a 19-year-old male vic-
tim of SCD  just as he had come out of a disco  
after a happy evening with friends, in which the 
autopsy examination revealed the presence of 
hypertrophic cardiomyopathy  is perhaps the 
most sensational case, but it is only the tip of 
the iceberg. SCD is not a single disease, but the 
outcome of a wide spectrum of diseases or 
conditions in which a substrate (genetic or ac-
quired) interacts with a series of physiological 
or pathophysiological factors (acute ischemia, 
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reperfusion, hyperadrenergic status, etc.) that 
modulate its arrhythmic propensity, in the pres-
ence of a triggering factor (Costantini 2019). 
This triad can lead to an intraventricular reentry 
(single or multiple), or result in post-potential 
triggered electrical activity, with the risk, in 
both cases, of producing a fatal arrhythmic ac-
cident. Such a paradigmatic sequence justifies 
most of the cases of sudden death, but the sub-
strate is age-dependent: up to 35 years of age, 
the prevailing substrate is represented by elec-
trical or structural alterations of the heart of ge-
netic origin; above the age of 35, it is mostly 
represented by the consequences of a coronary 
heart disease (Costantini 2019). An early recog-
nition of these arrhythmogenic conditions in 
the juvenile population could markedly reduce 
the risk of sudden death, as already evidenced 
in young athlete (Vetter 2014, 688–97).  Below 
we will consider some of the characteristics re-
lated to the main hereditary proarrhythmic 
conditions. 
 
Hypertrophic cardiomyopathy 
 
It is a hereditary disease of the heart muscle, 
caused by mutations in the genes that encode 
sarcomere proteins (Pasquale et al. 2012, 10–
17). The genetic abnormality results in a par-
ticular anatomical situation (myocardial hyper-
trophy, often asymmetric, sometimes mon-
strous; structural disorganization of the myofi-
brils, "disarray"; fibrosis) which determines a 
rather wide spectrum of functional and clinical 
alterations ranging from total asymptomaticity 
to myocardial ischemia, diastolic dysfunction, 
obstruction of left ventricular efflux, life-
threatening arrhythmias and  sudden death 
(Spirito, Quarta and Autore 2009, 1104–10). It 
is therefore a rather complex heart disease that 
has a high prevalence, estimated between 1/500 
and 1/1000. The disease often remains undiag-
nosed. The phenotypic aspects include left ven-
tricular hypertrophy, sometimes marked, often 
asymmetric, cavity of the left ventricle not di-
lated, conserved systolic function, dynamic ob-
struction in the left ventricular outflow tract (in 
20% of cases), electrocardiographic changes, 
arrhythmias, sudden death (Spirito, Quarta and 
Autore 2009, 1104–10). The clinical course is 
extremely variable. Many patients have normal 
life spans, remaining completely asymptomatic. 
Others develop heart failure, others die sud-
denly, often at a young age and without any 
warning symptoms. Massive hypertrophy and 
disarray, together with fibrosis, constitute a fa-
vorable substrate for several arrhythmogenic 
mechanisms that can be favored by intercurrent 
modulating factors (autonomous nerve factors, 
emotional stress, acute myocardial ischemia, 
electrolyte disturbances, drugs), with arrhyth-
mias of various kinds, up to malignant ventricu-
lar forms.  Usually the disease is suspected for 
the presence of a pathological ECG,  with QRS 
alterations (often Q of necrotic aspect) and 
ventricular repolarization alterations  (negative 
T waves in anteriorior and/or  lateral and/or  
inferior  leads, figure1) , during a screening for 
sports activity or for family history of hypertro-
phic cardiomyopathy or less often for symp-
toms (Migliore et al. 2012, 529–38). The diag-
nosis is then confirmed by an echocardiogram. 
In a minority of cases, a clearly pathological 
ECG is not followed by the presence of left 
ventricular hypertrophy at the echocardiogram 
(Spirito, Quarta and Autore 2009, 1104–10). In 
such cases (phenotypically incomplete) cardiac 
nuclear magnetic resonance may help. 
 
 
Figure 1. Classical ECG pattern in HCM 
 
Arrhythmogenic Right Ventricular Cardio-
myopathy/ Dysplasia (ARVD) 
 
ARVD is a progressive disease of myocardial 
tissue clinically characterized by ventricular ar-
rhythmias, heart failure, sudden death 
(Domenico Corrado and Thiene 2006, 1634–
37). The distinctive character of the disease is 
the replacement of cardiomyocytes with fibro-
adipose tissue with a particular structural and 
functional involvement of the right ventricle 
(but in more than half of the patients the left 
ventricle is also affected). In most cases it is a 
genetically determined inherited disorder with 
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autosomal dominant transmission caused by 
mutations in the genes encoding desmosomal 
proteins, plakoglobin, desmoplakina, plakofil-
ina-2, desmoglein-2 and desmocollin-2. The 
disease has a variable prevalence from 1/1000 
to 1/5000 subjects in the general population 
and represents one of the main causes of sud-
den death in athletes and young people. Clinical 
manifestations generally develop between the 
second and fourth decades of life and include 
palpitations, syncope, ventricular tachycardia, 
sudden death (D. Corrado et al. 2009, 1097–
1103). The morphological progression of the 
disease can lead to right or biventricular heart 
failure. In basal  ECG, abnormalities of various 
kinds are found in about 90% of cases, very 
useful both for making the diagnosis and for 
establishing the prognosis and the evolution of 
the disease (figure 2): P wave accentuated;  pro-
longed PR tract; extension of the QRS dura-
tion; right bundle branch block of varying de-
grees; presence of epsilon wave (small positive 
low voltage deflection in the final part of the 
QRS or at the beginning of the ST segment in 
the right precordials: it expresses delayed activa-
tion of portions of the right ventricle and corre-
sponds to the late recordable potentials with 
high resolution electrocardiography); negative T 
waves in the right precordial leads (D. Corrado 
et al. 2009, 1097–1103). The arrhythmic spec-
trum of the disease is variegated and ranges 
from ventricular, isolated or repetitive extrasys-
toles, sustained ventricular tachycardia, and 
ventricular fibrillation.     
 
 
Figure 2. ECG of a subject with ARVD. Note the 
altered QRS, with right bundle branch block and prob-
able epsilon wave in V1 
 
Brugada's syndrome 
 
It is a genetically based electrical disease that 
involves risk of sudden death (Brugada and 
Brugada 1992, 1391–96). The incidence of the 
condition is currently estimated around 5 cases 
per 10.000 (Antzelevitch et al. 2005, 429–40). 
Affected subjects have a defect in the gene that 
codes for the sodium channel:  its function is   
depressed, leading to a transmural electrical in-
homogeneity, which creates a voltage gradient 
between the epicardium and the endocardium.  
It is likely that the voltage gradient is due to an 
early repolarization in epicardial cells of the 
right ventricle: the genetic defect produces in 
these cells a deficit of sodium current during 
the phase 1 of the action potential, altering the 
balance between depolarizing and repolarizing 
forces, creating a strong predominance of the 
potassium repolarizing current (Ito). Since the 
subendocardial cells have a lower concentration 
of Ito channels, a clear difference in silhouette 
of the action potential between endocardium 
and epicardium takes place, producing voltage 
gradient, which favors the possibility of re-entry 
triggering in phase 2. 
Classically, three different types of Brugada’s 
patterns are derived from the basic ECG (Priori 
and Cerrone 2009, 1086–96): 
•Type 1: in this case it is evident a convex ele-
vation of the ST tract (coved type) of at least 
2 mm with evident J wave and negative T 
wave in V1 and / or V2 (figure 3); 
•Type 2: the ECG shows at V1 and / or V2 
an elevation of the point J of at least 2 mm 
and an elevation of the ST segment of at least 
1 mm and a positive or diphasic T wave; 
•Type3:  there is an elevation of the point J of 
less than 2 mm and a saddle back elevation of 
ST of less than 1 mm with a positive T wave 
in V1 and/or V2. 
 
Experts agree that only type 1 is diagnostic of 
syndrome (or pattern). Pattern 1, if not present 
in basal, can be disclosed by a pharmacological 
test, with flecainide or ajmaline, intravenously 
injected with great caution and under strict elec-
trocardiographic and clinical control. Some-
times the typical ECG alteration in right pre-
cordial derivations is absent or just mentioned 
but appears or becomes more striking if the 
electrodes of the precordial right V1 and V2 are 
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moved higher (Priori and Cerrone 2009, 1086–
96). The typical basal ECG aspect of the syn-
drome is not fixed, but it can suffer fluctuations 
(important to record ECG during fever). The 
sudden death is caused by a polymorphic ven-
tricular arrhythmia and occurs especially during 
sleep or rest. Fever can be a factor of risk for 
malignant ventricular arrhythmias in affected 
subjects. The transmission of the condition is 
autosomal dominant with age penetrance and 
sex-dependent: clinical manifestations are more 
common in adult subjects and are 8 times more 
frequent in men than women. Ventricular fibril-
lation occurs at an average age of 41 ± 10 years, 
but can appear at any age, usually at rest or dur-
ing sleep. Temperature, abuse of alcoholic bev-
erages and large meals can reveal the ST seg-
ment elevation, with type 1 –appearance and 
predispose to the onset of malignant arrhyth-
mias. Pharmacological treatments with drugs 
that produce an accentuation of the defect of 
the ion channels (such as sodium-blockers an-
tiarrhythmics), may represent a major risk in af-
fected patients (Priori and Cerrone 2009, 1086–
96). 
 
 
Figure 3. Classical Brugada’s-Type 1 pattern 
 
Congenital long QT syndrome (LQTS) 
 
Genetically transmitted electrical disease, char-
acterized by prolonged QT and high risk of ma-
lignant ventricular arrhythmias (torsade de 
pointes, which sometimes degenerates into ven-
tricular fibrillation). Most arrhythmias arise in 
conditions of mental or physical stress. The 
beta-blocker therapy markedly reduces the mor-
tality of this condition and therefore every ef-
fort is necessary for the diagnosis to be made in 
the affected persons (Schwartz, Periti and Mal-
liani 1975, 378–90). The genes involved are 
numerous, and hence the multiplicity of the va-
rieties already described , but the most frequent 
forms of LQTS are the first three varieties: the 
first two (LQTS 1 and LQTS 2)  derive from a 
genetic defect of potassium channels with loss 
of function; variety 3 (LQTS 3)  derives from a 
genetic defect of the sodium channel, with a 
gain in function (Schwartz and Crotti 2009, 
1071–78). 
PJ Schwartz proposed a very useful risk score 
for the cardiologist in diagnostic judgment (PJS 
score), which is based on the following ele-
ments: ECG and documented arrhythmias, 
medical history and family history (Schwartz 
and Crotti 2009, 1071–78).  A PJS score ≥3.5 
can be associated with a higher probability of 
disease presence. With a score between 1 to 3, 
the probability that the disease is present in the 
patient is intermediate, while a PJS score ≤1 
can be associated with a low probability of 
LQTS.  Often, a careful analysis of the ECG 
allows to differentiate between the various 
types of LQTS (at least among the main ones), 
therefore it is sometime possible to identify the 
genotype with a simple electrocardiogram 
(Schwartz and Crotti 2009, 1071–78). Thus, in 
type 1 a "homogeneous" elongation of the QT 
is classical, with evidence of very broad base T 
waves. In type 2 the presence of "notched" T in 
many derivations is characteristic (figure 4). In 
type 3 (the one that originates from an exalted 
sodium current and that responds less to beta-
blocking therapy) the late manifestation of the 
T wave is characteristic: it occurs late, after a 
long ST segment often quite isoelectric. The ex-
istence of gene-specific triggers of arrhythmic 
events, different in the various forms of con-
genital long QT, is demonstrated (Schwartz and 
Crotti 2009, 1071–78). Thus, subjects with 
LQT 1 are at higher risk of arrhythmias during 
exercise (especially during swimming). Subjects 
with LQT 2 are very sensitive to loud noises, 
especially during sleep. Subjects with LQT 3 are 
more at risk during sleep or rest. 
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Figure 4. Type 2 congenital long QT syndrome 
Short QT syndrome (SQTS) 
 
Short QT syndrome is a genetically transmitted 
disease represented by the association between 
a very short QT to the ECG together with a 
propensity to develop atrial and ventricular 
tachyarrhythmias, in the absence of cardiac 
structural alterations (Gussak et al. 2000, 99–
102). The mainstay of diagnosis of short QT 
syndrome is the 12-lead ECG: the diagnosis is 
made when duration of corrected QT is ≤340 
ms (figure 5).  Other features that may be seen 
on the ECG in short QT syndrome include tall, 
peaked T-waves and PR segment depression 
(Giustetto et al. 2006, 2440–47). The prevalence 
of SQTS in the population is likely around 
0,1%. The disease   appears to be associated 
with high lethality in all age groups, including 
children in early life. Criteria scientifically vali-
dated as independent risk factors for cardiac ar-
rest are lacking, and therefore remains to be 
clearly defined what is the optimal primary pre-
vention strategy in asymptomatic patients with 
this condition. No data are available to stratify 
the arrhythmic risk during competitive physical 
activity. Some reports show that quinidine is ef-
fective in prolonging the QTc interval and is 
likely to reduce arrhythmic events in these pa-
tients.    
 
 
 
Figure 5. ECG of a subject with short QT and atrial 
fibrillation. Atrial arrhythmias are common in short 
QT syndrome. 
 
All the conditions considered above have the 
prerogative of being able to be highlighted with 
an electrocardiogram: a simple and inexpensive 
gesture can therefore lead directly to the diag-
nosis or can make it suspect.  Diagnostic as-
sessment can minimize the risk of fatal events, 
through appropriate use of behavioral advice, 
drugs, devices, procedures.  There is a scientific 
evidence that ECG screening identifies athletes 
who are harboring potentially serious arrhyth-
mic events and that this strategy strongly re-
duces the incidence of SCD in competitive ath-
lete (Domenico Corrado et al. 2003, 1959–63); 
for these reasons, ECG screening in athletes is 
endorsed by learned scientific and sporting or-
ganizations.  Why then is a similar approach not 
extended to the entire youth population regard-
less of participation in an organized sports ac-
tivity program?    Something is indeed forgot-
ten:  although intense exercise in individuals 
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harboring quiescent cardiac pathology leads a 3-
fold greater risk of SCD in elite athletes com-
pared with non athletes, the majority of SCD in 
the young affect the general population  be-
cause  a lower   incidence    acts   on a broader  
population (Domenico Corrado et al. 2003, 
1959–63).  In most countries, young people are 
not offered cardiac screening unless they are 
engaged in top-level competitions, but this is in 
contrast, both ethically and legally, with the 
fundamental principle of equality of all indi-
viduals. Perhaps, it is time to reflect on the 
ECG screening of the entire youth population, 
not only of the athletes. In the 1960s the World 
Health Organization (WHO) adopted scientific 
criteria for the evaluation of health screening 
programs (A.a.v.v. 1968, 318).  
According to these criteria, a screening program 
is justified if:  
1) the morbid condition to be identified 
is relevant from a public health point of view;  
2) there is a proven efficacy test for the 
early identification of the morbid condition, to 
allow early treatment;  
3) there are effective therapeutic meas-
ures for the morbid condition if diagnosed at an 
early stage;  
4) there is evidence that such therapies, 
if started in the presymptomatic phase, im-
proves the clinical course and the prognosis of 
the morbid condition.  
We believe that all these criteria are met by an 
electrocardiographic screening in youth age and 
that also the cost-effective ratio would be ad-
vantageous (Domenico Corrado et al. 2011).  
    But a few important issues arise: 
1) What about false negatives? Some congenital 
conditions at risk of sudden death are not ac-
companied by alterations in the basic electro-
cardiogram. Among these, we must mention 
the Catecholaminergic Polymorphic Ventricular 
Tachycardia, the congenital anomalies of coro-
nary origin, the aortopathies. It should also be 
considered that even in the ECG-evident proar-
rhythmic conditions the diagnosis can escape 
due to the dynamic character of the ECG-
changes, which may be elusive at the time of 
screening (Priori and Cerrone 2009, 1086–96; 
Schwartz and Crotti 2009, 1071–78).  
 
2) What about false positives? The ECG is dy-
namic by nature: up to 7 years, T waves in the 
right precordials are physiologically negative; 
successively, they gradually positivize. When the 
T waves remain negative beyond V1 after the 
age of 14, is it necessary to question whether 
one is dealing with a juvenile pattern or ARVD 
(18).   Furthermore, regular and long-term in-
tensive exercise is associated with several elec-
trical manifestations that reflect enlarged car-
diac camber size and increase vagal tone 
(Chandra et al. 2014, 2028–34). To facilitate the 
interpretation of the ECG in athlete, the Euro-
pean Society of Cardiology has produced guide-
lines able to differentiate the normal ECG 
scheme belonging to the trained subject, from 
the one relative to a subject with an underlying 
heart disease, although a certain overlap can still 
be observed in some cases (Chandra et al. 2014, 
2028–34). 
 
    In addition to these, other issues of non-
negligible importance emerge, such as the 
amount of subjects considered positive at 
screening, who need further investigations or 
eventually therapeutic measures and follow-up , 
with relative costs and assumption of responsi-
bility by  the health system and operators. Last 
but not least, there is  a subtle question regard-
ing the psychological impact of screening: dis-
covering an arrhythmic  condition certainly has 
markedly positive aspects, but we should ask 
ourselves what psychological impact it could 
have on an asymptomatic individual and his 
family, learning from an unknown doctor that 
his heart is at risk of serious arrhythmias. 
 
In conclusions, prevention of SCD in young 
people, athletes and not, remains a high priority 
for the medical community. 
 We have the task of overcoming the difficulties 
and defining the most appropriate strategies to 
reach such an ambitious goal. 
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